2024年12月25日 · PLD1 (Phospholipase D1) is a Protein Coding gene. Diseases associated with PLD1 include Cardiac Valvular Dysplasia 1 and Heart Disease. Among its related pathways are Glycerophospholipid biosynthesis and Signaling by Rho GTPases.

2024年7月1日 · Aberrant dysregulation of phospholipase D (PLD) has been implicated in several malignancies, and oncogenic activation of this pathway facilitates tumor proliferation, stemness, and...

Phospholipase D1 (PLD1) is generally accepted as playing an important role in the regulation of multiple cell functions, such as cell growth, survival, differentiation, membrane trafficking, and cytoskeletal organization.

2017年2月17日 · PLD1 allosterically modulates the activity of mechanistic target of rapamycin (mTOR), which leads to the phosphorylation of CAD and enhances its catalytic activity.

PLD1 is threonine-phosphorylated in human-airway epithelial cells by a PKCdelta and src dependent mechanism; PLD1 may play a crucial role in collagen type I production through mTOR signaling in human dermal fibroblast. phospholipase D suppresses protein phosphatase 2A and is involved in the mTOR survival pathway in the transformation of human cells

2017年5月16日 · Phosphatidylcholine (PC)-specific phospholipases D (PLDs; EC 3.1.4.4) catalyze the hydrolysis of PC to produce phosphatidic acid and choline. A range of agonists acting through G protein-coupled receptors and receptor tyrosine kinases stimulate this hydrolysis.

2020年3月16日 · The signal transduction enzyme phospholipase D1 (PLD1) hydrolyzes phosphatidylcholine to generate the lipid second-messenger phosphatidic acid, which plays roles in disease processes such as...

2025年1月4日 · Title: PLD1 knockdown reduces metastasis and inflammation of fibroblast-like synoviocytes in rheumatoid arthritis by modulating NF-κB and Wnt/β-catenin pathways. RalA and PLD1 promote lipid droplet growth in response to nutrient withdrawal.

PLD1 and PLD2 have emerged as promising pharmaceutical targets with increased PLD1/2 activity and expression linked to tumor growth, neurodegeneration and various blood disorders.

Genetic and pharmacological targeting of PLD1 conferred protection against LPS-induced sepsis, cardiotoxin-induced muscle injury, and skin injury by promoting the shift toward M2; PLD2 ablation intensified disease severity by promoting the shift toward M1.